Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination

Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
New MS PATHS data was presented at ECTRIMS 2021

Biogen has announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS).

The results demonstrate that patients treated with Biogen’s portfolio of MS therapies mount an effective antibody response to COVID-19 vaccination.

The data is being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on 13-15 October 2021.